CD19 and acute lymphoblastic leukemia: In order to boost the effectiveness of humanized anti-CD19-CAR-T cells, individuals with refractory/relapsed (R/R) acute lymphoblastic leukemia are given extensive lymphodepleting chemotherapy regimens before receiving anti-CD19-CAR-T cell therapy (B-ALL).